Aclaris Therapeutics, Inc. (ACRS)
6.18
+0.16
(+2.66%)
USD |
NASDAQ |
Sep 02, 16:00
6.10
-0.08
(-1.29%)
After-Hours: 07:21
Aclaris Therapeutics Cash from Investing (Quarterly) : 10.26M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.26M |
| March 31, 2026 | -30.93M |
| December 31, 2025 | 10.37M |
| September 30, 2025 | 13.83M |
| June 30, 2025 | 5.047M |
| March 31, 2025 | 19.12M |
| December 31, 2024 | -88.72M |
| September 30, 2024 | 2.795M |
| June 30, 2024 | -0.674M |
| March 31, 2024 | 16.83M |
| December 31, 2023 | 7.55M |
| September 30, 2023 | 32.53M |
| June 30, 2023 | -19.66M |
| March 31, 2023 | 25.80M |
| December 31, 2022 | 2.702M |
| September 30, 2022 | 1.217M |
| June 30, 2022 | -21.22M |
| March 31, 2022 | 29.93M |
| December 31, 2021 | -9.176M |
| September 30, 2021 | -37.67M |
| June 30, 2021 | -45.47M |
| March 31, 2021 | -75.31M |
| Date | Value |
|---|---|
| December 31, 2020 | -2.305M |
| September 30, 2020 | 5.237M |
| June 30, 2020 | -10.49M |
| March 31, 2020 | 13.94M |
| December 31, 2019 | 56.44M |
| September 30, 2019 | 21.67M |
| June 30, 2019 | 18.95M |
| March 31, 2019 | 8.616M |
| December 31, 2018 | -70.51M |
| September 30, 2018 | 10.39M |
| June 30, 2018 | 13.29M |
| March 31, 2018 | 56.19M |
| December 31, 2017 | -21.56M |
| September 30, 2017 | -39.86M |
| June 30, 2017 | -0.226M |
| March 31, 2017 | 5.956M |
| December 31, 2016 | -77.82M |
| September 30, 2016 | -4.127M |
| June 30, 2016 | 9.868M |
| March 31, 2016 | 10.17M |
| December 31, 2015 | -69.49M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | -29.24M |
| Nektar Therapeutics | -399.11M |
| Xeris Biopharma Holdings, Inc. | -0.209M |
| Crinetics Pharmaceuticals, Inc. | 26.29M |
| Alumis, Inc. | 68.69M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.85M |
| Cash from Financing (Quarterly) | 0.091M |
| Free Cash Flow | -61.34M |
| Free Cash Flow Per Share (Quarterly) | -0.1395 |
| Free Cash Flow to Equity (Quarterly) | -19.77M |
| Free Cash Flow to Firm (Quarterly) | -19.90M |
| Free Cash Flow Yield | -7.68% |